Meeder Asset Management Inc Arbutus Biopharma Corp Transaction History

Meeder Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$3.11 - $4.61 $51,311 - $76,060	-16,499 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$2.65 - $4.62 $18,995 - $33,116	-7,168 Reduced 30.29%	16,499 $70,000
Q2 2021 Aug 09, 2021	BUY	$2.5 - $3.51 $59,167 - $83,071	23,667 New	23,667 $72,000
Q4 2019 Feb 13, 2020	SELL	$0.87 - $2.89 $4,972 - $16,519	-5,716 Closed	0 $0
Q3 2019 Oct 17, 2019	BUY	$1.34 - $2.4 $6,521 - $11,680	4,867 Added 573.26%	5,716 $9,000
Q2 2019 Aug 05, 2019	BUY	$1.46 - $4.44 $287 - $874	197 Added 30.21%	849 $2,000
Q1 2019 Apr 16, 2019	SELL	$3.41 - $4.57 $1,623 - $2,175	-476 Reduced 42.2%	652 $2,000
Q4 2018 Jan 17, 2019	SELL	$3.5 - $9.66 $16,709 - $46,116	-4,774 Reduced 80.89%	1,128 $3,000
Q3 2018 Nov 02, 2018	BUY	$7.85 - $12.35 $46,330 - $72,889	5,902 New	5,902 $0

138

95.5M

3.44M

377K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $576M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.